Diabetes Mellitus and Inflammatory Bowel Disease

NCT04105348 | Unknown

• 1 other identifier: DM and IBD
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Diabetes mellitus is a hyperglycemic metabolic disorder due to insulin deficiency or resistance at its receptors, leads to impaired glucose metabolism and multi-organ affection; (optic, peripheral neurological, cardiovascular and renal).

Conditions

Inflammatory Bowel Diseases

Outcome Measures

Primary Outcomes (1)

• effect of IBD on DM

  patients with raised; HbA1c, fasting blood glucose, 2 hours postprandial blood glucose

  on addmision

Study Arms (2)

IBD with DM

Diagnostic Test: HbA1c

IBD without DM

Diagnostic Test: HbA1c

Interventions

HbA1c DIAGNOSTIC_TEST

patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2

Also known as: fasting blood glucose, 2 hours postprandial blood glucose

IBD with DM; IBD without DM

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

IBD clinic or Patients addmited at El raghy hospital in assiut university with IBD

You may qualify if:

• \- All patients with IBD admitted at EL-Raghy Assiut university hospital in the period of first of October 2019 to the end of September 2020 The diagnosis of DM is confirmed by high random blood glucose level more than 200mg/dl three times per day or high HbA1c more than 6.5%.
• The diagnosis of IBD is confirmed by colonic biopsy results after colonoscopy.

You may not qualify if:

• Patients didn't do colonoscopy or didn't get biopsy or with normal colonoscopy and biopsy

Sponsors & Collaborators

• Assiut University: lead

Related Publications (5)

• Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.

  PMID: 29496507 BACKGROUND

• Basso PJ, Fonseca MT, Bonfa G, Alves VB, Sales-Campos H, Nardini V, Cardoso CR. Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. Braz J Med Biol Res. 2014 Sep;47(9):727-37. doi: 10.1590/1414-431x20143932. Epub 2014 Jul 25.

  PMID: 25075576 BACKGROUND

• Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr;96(4):1116-22. doi: 10.1111/j.1572-0241.2001.03756.x.

  PMID: 11316157 BACKGROUND

• Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol. 2012;25(1):37-44.

  PMID: 24714153 BACKGROUND

• van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009 Feb;39(2):81-93. doi: 10.1111/j.1365-2362.2008.02067.x.

  PMID: 19200161 BACKGROUND

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Central Study Contacts

Fatema Abd El-Moez, professor

CONTACT

00201006564000; fatemaelosily@yahoo.com

Lobna Ahmed, assisstant professor

CONTACT

00201093337630; lobna_wahid@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: September 24, 2019
• First Posted: September 26, 2019
• Study Start: October 1, 2019
• Primary Completion: June 1, 2021
• Study Completion: October 1, 2021
• Last Updated: October 1, 2019

Record last verified: 2019-09